Search clinical trials for: NNC 0123-0000-0338

Total 70 results

Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

United Kingdom
Novo Nordisk A/S

Completed

Safety of NNC 0123-0000-0338 in Healthy Subjects

Healthy | Diabetes

Germany
Janssen Research & Development, LLC

Completed

Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease

Inflammation | Crohn's Disease

Belgium, France, Israel, Hungary, Russian Federation, Poland, Canada, United States
Innate Pharma

Completed

Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
Novo Nordisk A/S

Completed

Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Spain, Germany, Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B (paradigm™ 3)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Turkey, Japan, South Africa, Romania
Novo Nordisk A/S

Completed

Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients (paradigm™ 2)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Germany, Macedonia, The Former Yugoslav Republic of, United Kingdom, Italy, Malaysia, Hungary, Thailand, France, Russian Federation, Turkey, Japan, South Africa, Canada
Novo Nordisk A/S

Completed

Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. (paradigm™5)

Congenital Bleeding Disorder | Haemophilia B

United States, Canada, United Kingdom, France, Malaysia, Brazil, Croatia, Germany, Italy, Japan, Taiwan
Novo Nordisk A/S

Completed

Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 (paradigm™ 4)

Congenital Bleeding Disorder | Haemophilia B

United States, Netherlands, Austria, Spain, Germany, Macedonia, The Former Yugoslav Republic of, Taiwan, United Kingdom, Italy, Malaysia, Thailand, France, Greece, Russian Federation, Turkey, Japan, South Africa, Romania
Novo Nordisk A/S

Completed

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. (pathfinder™3)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, United Kingdom, Croatia, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Italy, Japan, Norway, Bulgaria
Novo Nordisk A/S

Terminated

Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Withdrawn

Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers

Obesity | Metabolism and Nutrition Disorder
Novo Nordisk A/S

Completed

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A (pathfinder™2)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, Japan, United Kingdom, Croatia, Italy, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Puerto Rico, Norway, Korea, Republic of, Bulgaria, Russian...
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A (pathfinder™6)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Austria, Spain, Taiwan, Japan, Italy, Bulgaria, Malaysia, Algeria, Australia, Canada, Israel, Thailand, Argentina, Greece, Romania, Germany
Novo Nordisk A/S

Completed

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A (pathfinder™5)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Switzerland, Malaysia, Brazil, Canada, Japan, United Kingdom, Israel, Portugal, Ukraine, Greece, Lithuania, Puerto Rico, Turkey, Italy
Novo Nordisk A/S

Completed

Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A (pathfinder™1)

Congenital Bleeding Disorder | Haemophilia A

United States, Germany, Switzerland, United Kingdom, Italy, Japan, Turkey
Novo Nordisk A/S

Completed

A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

United Kingdom, Romania, Poland, Denmark, Czech Republic, Hungary
Novo Nordisk A/S

Completed

Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Terminated

A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects

Inflammation | Healthy | Rheumatoid Arthritis | Systemic Lupus Erythematosus

Netherlands
Novo Nordisk A/S

Withdrawn

An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)

Inflammation | Systemic Lupus Erythematosus

United States
Novo Nordisk A/S

Completed

Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

Non-Hodgkin Lymphoma | NK/T Cell Lymphoma | Vascular Immunomother T Cell Lymphoma

China
Novo Nordisk A/S

Completed

Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (Explorer 1)

Healthy | Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

Austria, Sweden, Spain, Switzerland, United Kingdom, Germany, Malaysia, Denmark, South Africa, Thailand, Italy
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Non Hodgkin Lymphoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

Phase Ib/II Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Non-hodgkin's Lymphoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Primary Central Nervous System Lymphoma | Secondary Central Nervous System Lymphoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc.

Recruiting

A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

China
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0362 in Healthy Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
University of Melbourne
Merck Sharp & Dohme LLC; The Alfred

Terminated

Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART

HIV Infections

Australia
Claude Bernard University
University of Nancy

Recruiting

Toothbrushes in Daily Practice in Patients With Fixed Orthodontic Appliances (ORTHO-IOP)

Dental Malposition

France
The Netherlands Cancer Institute

Recruiting

Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer (CisCon)

Fallopian Tube Carcinoma | Peritoneal Cancer | FIGO Stage III Ovarian Cancer

Netherlands
Grifols Therapeutics LLC

Completed

Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration

Macular Degeneration

Germany
Magna Pharmaceuticals, Inc.

Withdrawn

Study of AHIST in Seasonal Allergic Rhinitis Patients

Rhinitis, Allergic, Seasonal

United States
Calvary Hospital, Bronx, NY
New York State Department of Health; RTS Family Foundation

Completed

Effect of Intermittent Pneumatic Compression on Ulcer Healing in Subjects With Secondary Lymphedema

Lymphedema

United States
Grifols Therapeutics LLC

Completed

A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency

Immunologic Deficiency Syndrome

United States, Canada
University Hospital Heidelberg
ZOLL Circulation, Inc., USA

Unknown

Hypothermia in Acute Ischemic Stroke - Surface Versus Endovascular Cooling (HAIS-SE) (HAIS-SE)

Ischemic Stroke | Hypothermia | Thrombolysis

Germany
Claude Bernard University
Elsan; University of Nancy

Enrolling by invitation

Pregnancy Women and Individual Oral Prophylaxis in the Control of Gingival Inflammation (PRE-IOP) (PRE-IOP)

Pregnant Woman

France
Schön Klinik Berchtesgadener Land

Completed

Effects of Supplemental Oxygen Delivered by a Portable Oxygen Concentrator Compared to a Liquid Oxygen Device in COPD

Chronic Obstructive Pulmonary Disease

Germany
Medtronic Xomed, Inc.
Medtronic

Terminated

Study of Polyester Implants for the Treatment of External Nasal Valve Collapse (NVC) (NVC)

Nasal Alar Collapse, Bilateral

United States
Sam Brophy

Completed

Transcutaneous Electrical Nerve Stimulation for Back Pain in the Emergency Department (TENS-ED) (TENS-ED)

Lower Back Pain | Muscle Pain | Back Pain | Acute Pain | Lower Back Pain Mechanical

Canada
Grifols Therapeutics LLC

Completed

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis (PRIVIG)

Multiple Sclerosis, Relapsing-Remitting

Canada, Israel, United States, Austria, Czech Republic, Germany, Greece, Hungary, Poland, Slovakia, Sweden, United Kingdom
Grifols Therapeutics LLC

Completed

Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP

Purpura, Thrombocytopenic, Idiopathic

United States
Grifols Therapeutics LLC

Completed

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ICE)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

United States, Israel, Germany, Czech Republic, Mexico, Argentina, Canada, Italy, Poland, Serbia
Infrared Cameras Incorporate

Completed

A Study to Validate Comparability of an Infrared Thermographic Camera Versus Oral, Forehead, and Ear Thermometers When Determining Body Temperature in Adult Participants

Temperature Change, Body

United States
University of Alabama at Birmingham
Tufts University; University of Minnesota

Completed

Predictors of Response to Fenofibrate (PreFar)

Insulin Resistance | Hypertriglyceridemia

United States
Grifols Therapeutics LLC

Completed

Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)

Alpha 1-Antitrypsin Deficiency

Denmark, Sweden, United Kingdom
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

The Influence of Chronic CMV Infection on Influenza Vaccine Responses (SLVP025)

Influenza | Cytomegalovirus Infections

United States
Wake Forest University Health Sciences

Active, not recruiting

SNIFF Multi-Device Study 2

Cognitive Impairment | Mild Cognitive Impairment

United States
University of Southern Denmark
Odense University Hospital; University of Salford; Sygehus Lillebaelt; Region of... and other collaborators

Completed

Gait Analysis and Interdisciplinary Interventions for Children With Cerebral Palsy (CPinMotion)

Cerebral Palsy

Denmark

Search clinical trials for: NNC 0123-0000-0338

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations